Search results for: Multi-Indication Medicines
Filter search results
OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates
3 December 2021
…directly set prices for branded medicines. Such policies would reduce global pharmaceutical revenues, leading to a reduction in pharmaceutical R&D expenditure and ultimately to lower levels of innovation. To support…
ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
6 June 2022
…indicated for rare diseases and as such, they face the same challenges as other orphan medicines. The aim of the panel was to discuss how HTA should evolve to enable…
Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
12 January 2013
…£12,936, as a result of NICE approving a new medicine, will lead to the loss of one quality-adjusted life-year (QALY). Therefore, they conclude, NICE should not approve medicines with a…
Value Based Pricing in Sweden: Lessons for Design?
11 January 2012
…in Sweden has been successful. It has avoided critics’ fears that the result would be rapid rises in medicines spending and has found mutually acceptable solutions for rewarding innovation and…
General Practice Today
1 July 1968
…time-consuming and heroic, if relatively ineffective, treatment. Now illness is often contained quickly before it becomes serious and is usually treated by the administration of effective medicines, such as antibiotics,…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 April 2012
…pricing (VBP) framework for efficient use and pricing of medicines also might be applied to diagnostics. We recommend a two-part approach. First, in the case of companion diagnostics introduced at…
Building for Health
1 July 1970
…capital assets. For example, with the development of medicines and other means of combatting tuberculosis, the old sanitoria are no longer necessary. The success of poliomyelitis vaccination has meant the…
Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society
1 November 2010
…followed by having access to the centralised procedure. The number of medicines available in Europe to treat rare diseases has risen from only eight in 2000 to 68 by the…
Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries
1 November 2009
…are based primarily on clinical evidence, countries are flexible in their criteria and their approach, accepting lower risk-benefit ratios for OMPs than for other new medicines. When a formal health…